Actions

CD22: Difference between revisions

From haematologyetc.co.uk

No edit summary
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 46: Line 46:
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
|-
!colspan="8"|<span style="font-size:100%">'''Expression in primitive cell types'''</font>
!colspan="8"|'''Expression in primitive cell types'''</font>
|-  
|- <span style="font-size:70%">
! AML !! CMML !! B ALL !! Burkitt || T ALL !! ETP ALL <'''[[ETP ALL|I]]'''> !! MPAL <'''[[MPAL|I]]'''> || Hgns <'''[[Hgns|I]]'''>
!AML!!CMML !!B ALL !!BL ||T ALL !!ETP ALL !!MPAL ||Hgn</span>
|-
|-<span style="font-size:70%">
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #66e0ff; color:black"|20-40%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|-
|-
|}
|}


<span style="font-size:90%">'''Notes:''' xxxxx </span>
<span style="font-size:90%">'''Notes:''' Expression of CD22 is a feature of B-lineage commitment that is not essential for diagnosis, but strongly suggests B lineage. Aberrant expression is uncomon and should suggest the possibility of MPAL </span>




Line 67: Line 67:
|-
|-
!colspan="8"|'''Expression in mature B cell neoplasms'''
!colspan="8"|'''Expression in mature B cell neoplasms'''
|-  
|- <span style="font-size:70%">
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|-<span style="font-size:70%">
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #004466; color:white"|80-100%
|style="width: 12.5%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 12.5%; background: #E6FAFF; color:black"|<5%
|-
|-
|}
|}


<span style="font-size:90%">'''Notes:''' xxxxx </span>
<span style="font-size:90%">'''Notes:''' The level of expression may vary both between and within cases of mature B cell neoplasm, but expression tends to be lost by mature plasma cells </span>




Line 91: Line 91:
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|-
|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: ?#FFE4E1 5#E6FAFF 20#66e0ff 40#00b8e6 80#006699;100#004466; color:white black"|? <5% 5-20% 20-40% 40-80% 80-100%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|-
|-
|}
|}


<span style="font-size:90%">'''Notes:''' xxxxx </span>
<span style="font-size:90%">'''Notes:''' Expression of CD22 is uncommon in mature T cell disorders </span>


----
----

Latest revision as of 21:39, 4 July 2023


Summary
CD22 expression is largely restricted to B-lymphocytes
The major value of CD22 lies in the identification of ALL based on high lineage-specificity and very early acquisition in cytoplasm followed by cell surface expression



Normal expression and function

CD22 is a membrane adhesion receptor whose expression is mostly restricted to B lymphocytes where it is believed to be a negative regulator of activation. Expression is developmentally related - first appearing in cytoplasm of pro-B cells then on the surface in pre-B cells. CD22 is fully expressed by mature-B cells, but is lost during plasma cell differentiation.


Diagnostic role

  • Cytoplasmic expression of CD22 gives particular value in the detection of pro-B ALL where diagnosis requires expression at least two of three markers: CD22 (membrane or cytoplasm), CD19 or CD79a. CD22 may not be uniformly expressed across a cell population with expression often being seen on only 60-90 of cells
  • in mature B cell neoplasms CD22 has relatively low expression in CLL, MCL and FL, but has high expression in HCL



Other relevant information:

Basophils express CD22



SUMMARY TABLES


Note The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click here. For further information about a particular disease state click <I> adjacent to the condition name


Expression in primitive cell types
AML CMML B ALL BL T ALL ETP ALL MPAL Hgn
<5% <5% 80-100% 80-100% <5% <5% 20-40% 80-100%

Notes: Expression of CD22 is a feature of B-lineage commitment that is not essential for diagnosis, but strongly suggests B lineage. Aberrant expression is uncomon and should suggest the possibility of MPAL


Expression in mature B cell neoplasms
CLL MCL FL MZL HCL DLBCL LPL PCL
80-100% 80-100% 80-100% 80-100% 80-100% 80-100% 80-100% <5%

Notes: The level of expression may vary both between and within cases of mature B cell neoplasm, but expression tends to be lost by mature plasma cells


Expression in mature T cell neoplasms*
ATLL CTCL/Sezary T-PLL T-LGL NK-LGL
<5% <5% <5% <5% <5%

Notes: Expression of CD22 is uncommon in mature T cell disorders

Retrieved from ‘https://haematologyetc.co.uk/index.php?title=CD22&oldid=2229’